In Vivo Evaluation of VEGF-Targeted Bispecific Antibodies

As PD-1/PD-L1 x VEGF-targeted bispecific antibodies gain momentum in oncology, selecting the right preclinical models is becoming increasingly important. These therapies are designed to simultaneously target tumor angiogenesis and immune suppression, making robust in vivo models essential for evaluating both antitumor activity and immune modulation.

WuXi Biology and Testing offers a broad portfolio of humanized mouse models spanning numerous tumor types to support the preclinical evaluation of PD-1/PD-L1 x VEGF-targeted bispecific antibodies. Our capabilities include PBMC humanized models across multiple tumor types, enabling assessment of tumor growth inhibition and immune-related pharmacodynamic endpoints to provide a more complete understanding of therapeutic response.